Philip D Gregory
CIK 1343543 · Chief Scientific Officer · last filed 2024-01-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLUE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
501 CANAL BOULEVARD SUITE A100
RICHMOND, CA 94804
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| 2seventy bio, Inc. (TSVT) Delisted | Chief Scientific Officer | 310,280 | $5.00 | $1.55M | -$317.2K | 12 | 2024-01-09 |
| bluebird bio, Inc. (BLUE) Delisted | Chief Scientific Officer | 1,706 | $4.97 | $8.5K | -$10.56M | 66 | 2021-11-17 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | SVP of Research & CSO | 131,410 | $0.18 | $23.3K | -$5.88M | 59 | 2015-06-03 |
Recent Filings · Page 10 of 14
137 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-07-03 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$150.0K | EDGAR |
| 2014-03-25 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$221.1K | EDGAR |
| 2014-02-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$226.1K | EDGAR |
| 2014-01-03 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$147.0K | EDGAR |
| 2013-12-13 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | +19,347 | -$189.7K | EDGAR |
| 2013-12-04 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$118.5K | EDGAR |
| 2013-11-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$87.7K | EDGAR |
| 2013-10-04 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$94.2K | EDGAR |
| 2013-09-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$91.1K | EDGAR |
| 2013-08-05 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$84.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.